August 5

Bayswater Confirms Discovery of Strong Uranium Targets at Brudell Lake Project in Athabasca Basin

Drilling at Collins Bay Extension Encounters Uranium

Bayswater Uranium Corporation (TSX-V: BAY) (PINKSHEETS: BYSWF) is pleased to report that interpretation of ground geophysical surveys has detected strong conductors at the Brudell Lake Project, and that diamond drilling at the Collins Bay Extension Project has defined anomalous uranium concentrations in favourable lithological and structural settings.

Brudell Lake Project

The Brudell Lake Project is located in the west-central part of the Athabasca Basin in northern Saskatchewan midway between the Shea Creek deposits currently being developed by Areva and UEX (TSX: UEX), and the Centennial Deposit being evaluated by Cameco (TSX: CCO) and partners.
Read more: Bayswater Uranium Corporation ( BAY )
August 5

MedMira Extends Market Reach into Southeast Asia with Contract for One Million HIV Tests

SE Asia Latest Target Market in Growing Global Distributor Network

MedMira Inc., (\"MedMira\") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it has expanded its global distribution network into Southeast Asia, where the Company\'s MiraWell(R) Rapid HIV Test (MiraWell HIV) will soon be available to healthcare providers and their patients.

American Health Diagnostics LLC (AHD), a MedMira distribution agent in the United States, has signed an exclusive distribution agreement for MiraWell HIV in select markets of the Southeast Asia region. Under the terms of the agreement AHD will purchase one million MiraWell HIV tests in the first year. Technical training is slated to begin in August 2008 with product sales ramping up throughout the year. AHD is working with its on-the-ground sub-distributors, to market, sell and promote MiraWell HIV in the territory.
Read more: MedMira Inc ( MIR )
August 5

Goldsource Intercepts 36.8 Metres of Continuous Coal: Border Property, Saskatchewan

Goldsource Mines Inc. (the \"Company\") (TSX VENTURE:GXS) announces that it has completed hole BD08-05, offset hole BD08-03A and hole BD08-07 at the Border Property near Hudson Bay, Saskatchewan (see attached drill plan, available at: http://media3.marketwire.com/docs/gxs0805plan1.pdf).

- BD08-05 36.8 metre coal seam with 36.8 metres of continuous coal with minor partings. - BD08-03A 25.2 metre coal seam with 22.1 metres of continuous coal with minor partings. - BD08-07 3.0 metres mudstone/sandstone with coal.
Read more: Goldsource Mines Inc ( GXS )
August 5

Columbia Yukon Explorations Inc.: 2008 NI 43-101 Report Delivers Impressive Resource Reclassification for Storie Property

Columbia Yukon Explorations Inc. (TSX VENTURE:CYU)(FRANKFURT:VOR) (the \"Company\" or \"Columbia Yukon\") is extremely pleased to announce a significant advancement of the Company\'s \"Storie\" molybdenum property deposit.

As previously reported, Watts, Griffis and McOuat Limited (\"WGM\"), Consulting Geologists and Engineers of Toronto, Ontario, and Mintec, Incorporated of Tucson, Arizona, (\"Mintec\"), were retained by Columbia Yukon to prepare an updated NI 43-101 Mineral Resource estimate for the Storie molybdenum property deposit based on the results of historical drilling by Shell Canada in 1979 and 1980 and drilling completed by the Company in 2006 and 2007. The new report (the \"WGM Report\") was commissioned, in part, for the objective of reclassifying the Mineral Resource of the Storie molybdenum deposit from an Inferred category to Indicated and Inferred categories. The updated NI 43-101 report has been prepared by Robert M. Kuehnbaum, P.Geo., Senior Associate Geologist with WGM and Abdullah Arik, AusIMM, Principal MineSight Specialist with Mintec.
Read more: Columbia Yukon Explorations Inc ( CYU )
August 5

ProMetic Reaches Understanding for Commercialization of Several Biopharmaceutical Products and Strategic Investment

ProMetic Life Sciences Inc. (TSX: PLI) (\"ProMetic\") announces today that it has reached an understanding with a fully integrated, U.S.-based, biotechnology company with respect to the development and global commercialization of several biopharmaceutical products in ProMetic\'s Protein Technology Division.

In addition to licensing, development and milestone fees as well as on-going royalties on sales of products, the definitive agreements will provide for an initial strategic investment in ProMetic of $7 million at a share price of $0.47. This transaction is anticipated to provide a significant funding commitment towards the development and commercialization of the products, which will contribute to ProMetic\'s revenue growth as early as 2008.
Read more: ProMetic Life Sciences Inc ( PLI )